Yohann Loriot

29PUBLICATIONS
397CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 15, 2026
Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts.

|Jul 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung Cancer.

|Jun 25, 2026
Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.

|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

|Feb 03, 2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé

Pageof 5

Frequent Collaborators

10 joint publications

Benjamin Besse

8 joint publications

Luc Friboulet

8 joint publications

Fabrice Andre

6 joint publications

Jean-Yves Scoazec